Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

NeoStem Names Robert Dickey IV As CFO - Quick Facts

RELATED NEWS
Trade NBS now with 

NeoStem Inc. (NBS: Quote) announced that it has appointed Robert Dickey IV as Chief Financial Officer, effective today.

NeoStem stated that Larry May, the company's long-time Chief Financial Officer, is assuming the newly-created position of Vice President, Strategic Initiatives, and will assist Dickey in the transition as well as focus on the company's various strategic activities.

Dickey has over 15 years of management experience at life sciences companies, including positions as a CFO, COO and CEO and board member, following a career as an investment banker.

He has specific expertise in financing, M&A, partnering/licensing transactions and project management, as well as international experience.

Dickey is joining NeoStem from Hemispherx Biopharma, Inc. where he served as Senior Vice President. Prior to Hemispherx , Dickey was Senior Vice President, Chief Financial Officer and Business Unit Manager at StemCyte Inc. Other management experience includes leadership positions at Protarga Inc, and Locus Pharmaceuticals. Previously, he spent 18 years as an investment banker, 14 of those at Lehman Brothers, with a background split between M&A and capital markets transactions across a variety of industries.

Register
To receive FREE breaking news email alerts for Neostem Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.